VEGFA and head and neck squamous cell carcinoma: The efficacy of VEGF inhibitors has been somewhat disappointing in this space as well, with Bevacizumab in combination with chemotherapy affording marginally improved ORR of 9% and PFS of 1.7 months when compared to chemotherapy alone; and no improved survival in heavily pre-treated HNSCC [70].